Skip to main content

Table 1 Baseline demographic and disease characteristics of the Chinese subpopulation of the JACOB trial (ITT population)

From: Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

Characteristic Total (cases) Pertuzumab group [cases (%)] Control group [cases (%)]
Total 163 82 81
Age
 < 65 years   61 (74.4) 62 (76.5)
 ≥ 65 years   21 (25.6) 19 (23.5)
Sex
 Male 130 59 (72.0) 71 (87.7)
 Female 33 23 (28.0) 10 (12.3)
Disease measurability
 Measurable 144 74 (90.2) 70 (86.4)
 Non-measurable 19 8 (9.8) 11 (13.6)
ECOG PS
 0 47 24 (29.3) 23 (28.4)
 1 116 58 (70.7) 58 (71.6)
Histological subtype (Lauren classification)
 Diffuse 16 9 (11.0) 7 (8.6)
 Intestinal 144 71 (86.6) 73 (90.1)
 Mixed 3 2 (2.4) 1 (1.2)
Primary site
 Gastroesophageal junction 33 21 (25.6) 12 (14.8)
 Stomach 130 61 (74.4) 69 (85.2)
Number of metastatic sitesa
 1–2 139 68 (82.9) 71 (88.8)
 > 2 23 14 (17.1) 9 (11.3)
HER status
 IHC2+ and ISH+ 31 14 (17.1) 17 (21.0)
 IHC3+ 132 68 (82.9) 64 (79.0)
Prior gastrectomy
 Yes 47 23 (28.0) 24 (29.6)
 No 116 59 (72.0) 57 (70.4)
  1. ITT intention to treat; ECOG PS Eastern Cooperative Oncology Group performance status; HER2 human epidermal growth factor receptor 2; IHC immunohistochemistry; ISH in situ hybridization
  2. aOne patient in the control group did not have data on the number of metastatic sites available